SCHEMBL29574489

SCHEMBL29574489

COC(=O)c1ccncc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
ALDH1A1 P00352 3/20 0.64
GLA P06280 2/20 0.64
GAA P10253 2/20 0.64
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HSD17B10 Q99714 4/20 0.47
KMT2A Q03164 2/20 0.44
CYP46A1 Q9Y6A2 1/20 0.44
KDM4C Q9H3R0 1/20 0.43
HTT P42858 2/20 0.42
HPGD P15428 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
NCOA1 Q15788 1/20 0.42
RCE1 Q9Y256 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42
MAP2K1 Q02750 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359044 1.00 KDM4E (0.64) KDM4EALDH1A1GLAGAALMNA
Hydrochloric Acid SCHEMBL2900807 0.98 KDM4E (0.62) KDM4EALDH1A1GLAGAALMNA
SCHEMBL2419079 0.85 KDM4E (0.59) KDM4EALDH1A1GLAGAALMNA
Bromide SCHEMBL21816290 0.84 KDM4E (0.57) KDM4EALDH1A1GLAGAALMNA
SCHEMBL68952 0.82 KDM4E (0.70) KDM4EALDH1A1GLAGAALMNA
SCHEMBL29416299 0.82 KDM4E (0.70) KDM4EALDH1A1GLAGAALMNA
SCHEMBL23970755 0.81 ALDH1A1 (0.42) KDM4EALDH1A1GLAGAALMNA
SCHEMBL629401 0.81 TSHR (0.50) KDM4EALDH1A1GLAGAAHSD17B10
SCHEMBL3028074 0.79 KDM4E (0.66) KDM4EALDH1A1GLAGAALMNA
SCHEMBL9107394 0.79 KDM4E (0.66) KDM4EALDH1A1GLAGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743457-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE 4M THERAPEUTICS INC. (US) 2026-05-20 EP disclosed
EP-4584267-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 EP disclosed
WO-2025015045-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE 4M THERAPEUTICS INC. (US) 2025-01-16 WO disclosed
WO-2024052692-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
US-20240083896-A1 Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-03-14 US disclosed
EP-4255573-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2023-10-11 EP disclosed
WO-2023126951-A1 INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-07-06 WO disclosed
WO-2023067515-A1 THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
WO-2022118210-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2022-06-09 WO disclosed
EP-3976608-A1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2022-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083896-A1 Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors SCN8A, SCN1A, SCN2A KDM4E 2568/4885ALDH1A1 1362/4885GLA 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.